Discover and read the best of Twitter Threads about #kcsm
Most recents (4)
In May 2019, Dr. @rschilsky & I co-chaired the #AAADV19 Workshop Plenary Session "Decentralized #ClinicalTrials: The Future is Now." An incredible group of panelists from academia, industry, govt, & patient #advocacy 👇discussed the rationale, challenges, & opportunities of DCTs. 
No one knew yet that the #COVID19 #pandemic was just around the corner. In Mar 2020, FDA released a guidance on conduct of #clinicaltrials during the pandemic: fda.gov/media/136238/d…, & colleagues wrote about the impact on #OncTwitter trials: ncbi.nlm.nih.gov/pmc/articles/P…. /2
FDA has now released a draft guidance on decentralized #clinicaltrials for drugs, biological products, & devices covering #telehealth, remote assessments, consent, shipping of IP, & more: fda.gov/media/167696/d…. #MedTwitter #regulatory #drugdevelopment
Radiotherapy for renal cell carcinoma: current status and future directions
#RadOnc #kcsm #KidneyCancer @ASTRO_org @ESTRO_RT @ARRO_org @RadoncUh
Thread🧵
#RadOnc #kcsm #KidneyCancer @ASTRO_org @ESTRO_RT @ARRO_org @RadoncUh
Thread🧵
Thanks to @_ShankarSiva @DrAlexLouie @rob_uzzo @uretericbud @whallradonc @LPonsky @LeilaTchelebi for improving quality of this talk.
Thanks to @AmarUKishan @UCLA for invite to present.
Thanks to @AmarUKishan @UCLA for invite to present.
For reference, kidney cancer staging is here.
Currently, role of #radonc is for smaller cancers (eg, T1a/b, some T2) and metastatic disease.
Currently, role of #radonc is for smaller cancers (eg, T1a/b, some T2) and metastatic disease.
Is there a role for Local Tx of the Primary Tumor for Patients with Metastatic Cancer?
🚫Many studies demonstrate no benefit.
📌We performed a MetaAnalysis to evaluate the average effect of Local Tx across various tumors.
A thread🧵#AMSM #PRIMETX
redjournal.org/article/S0360-…
1/25
🚫Many studies demonstrate no benefit.
📌We performed a MetaAnalysis to evaluate the average effect of Local Tx across various tumors.
A thread🧵#AMSM #PRIMETX
redjournal.org/article/S0360-…
1/25
Critics of Local Tx to the Primary Tumor
📌 Many providers think local control of the primary tumor in the setting of M1 dz is akin to “closing the barn door after the horse has bolted”
📌 Ian Tannock wrote a fantastic article on this back in 2000.
pubmed.ncbi.nlm.nih.gov/11759650/
2/
📌 Many providers think local control of the primary tumor in the setting of M1 dz is akin to “closing the barn door after the horse has bolted”
📌 Ian Tannock wrote a fantastic article on this back in 2000.
pubmed.ncbi.nlm.nih.gov/11759650/
2/
Supporters of Local Tx
📌Some support aggressive ablation of all sites due to the enhanced ability to detect occult disease with improved imaging technologies and 📉 toxicities with complete ablation.
pubmed.ncbi.nlm.nih.gov/35831494/
pubmed.ncbi.nlm.nih.gov/31182289/
pubmed.ncbi.nlm.nih.gov/34742582/
3/
📌Some support aggressive ablation of all sites due to the enhanced ability to detect occult disease with improved imaging technologies and 📉 toxicities with complete ablation.
pubmed.ncbi.nlm.nih.gov/35831494/
pubmed.ncbi.nlm.nih.gov/31182289/
pubmed.ncbi.nlm.nih.gov/34742582/
3/
1/ Our latest work was just published in @NatureMedicine!
Congratulations to first author Super-Star @BraunMDPhD and to all authors. #CathyWu #SachetShukla @LabSignoretti @VanAllenLab #FreemanLab #SharpeLab
@DanaFarberNews @DanaFarber
#kcsm #KidneyCancer
doi.org/10.1038/s41591…
Congratulations to first author Super-Star @BraunMDPhD and to all authors. #CathyWu #SachetShukla @LabSignoretti @VanAllenLab #FreemanLab #SharpeLab
@DanaFarberNews @DanaFarber
#kcsm #KidneyCancer
doi.org/10.1038/s41591…
2/ Our study analyzes patient samples from 3 prospective clinical trials of PD-1 blockade.
The study includes 592 tumors that were profiled by WES, RNA-seq, and/or IF for CD8+ T cells on samples collected before treatment with Nivolumab (anti-PD1) or Everolimus (mTOR inhibitor)
The study includes 592 tumors that were profiled by WES, RNA-seq, and/or IF for CD8+ T cells on samples collected before treatment with Nivolumab (anti-PD1) or Everolimus (mTOR inhibitor)
3/ We evaluated genomic correlates of response to PD-1 inhibitors in ccRCC.
Molecular features that had been previously suggested to correlate with outcomes (e.g. TMB, NeoAg load) were not found to be predictive of benefit from PD-1 blockade.
Molecular features that had been previously suggested to correlate with outcomes (e.g. TMB, NeoAg load) were not found to be predictive of benefit from PD-1 blockade.
